reports
Updated: Myriad Genetics to Participate in Two Upcoming Investor Healt...
Updated: Myriad Genetics to Participate in Two Upcoming Investor Healthcare Conferences Correction: Time of BofA Conference SALT LAKE CITY, May 14, 2025 (GLOBE NEWSWIRE) -- . (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced that management plans to participate in the following investor healthcare conferences: The BofA Securities 2025 Health Care Conference – fireside chat at 6:00 pm ET (updated) on Wednesday, May 14, 2025.Goldman Sachs 46th Annual Global Healthcare Conference – fireside chat at 2:00 pm ET on Wednesday, June 11, 2025. Liv...
Myriad Genetics Announces RiskScore Study Published in JCO Precision O...
Myriad Genetics Announces RiskScore Study Published in JCO Precision Oncology Study suggests that utilizing RiskScore drives breast cancer screening tailored to individual risk SALT LAKE CITY, May 07, 2025 (GLOBE NEWSWIRE) -- . (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, announced today that JCO Precision Oncology published a real-world suggesting that the results of RiskScore® led clinicians to recommend breast cancer screening aligned with patients’ individual risk. RiskScore, Myriad’s clinically validated breast cancer risk assessment tool integ...
Myriad Genetics Reports First Quarter 2025 Financial Results; Updates ...
Myriad Genetics Reports First Quarter 2025 Financial Results; Updates 2025 Financial Guidance Highlights First quarter 2025 revenue of $196 million declined by 3% year-over-year. Excluding headwinds1 of $16 million, revenue increased 5% year-over-year.First quarter 2025 Prenatal revenue grew 11% year-over-year, while Pharmacogenomics revenue declined by 20% year-over-year due to UnitedHealthcare (UNH) reducing coverage of GeneSight®. MyRisk®testing volume in the affected population grew 11% year-over-year. First quarter 2025 gross margin of 69% increased 40 basis points year-over-year, ben...
Concerns about Mental Health Medication Side Effects Remain a Barrier ...
Concerns about Mental Health Medication Side Effects Remain a Barrier to Getting Help for Those Diagnosed with Depression and Anxiety, According to the GeneSight Mental Health Monitor More than half say genetic testing for mental health medications could reduce concerns SALT LAKE CITY, April 30, 2025 (GLOBE NEWSWIRE) -- Nearly nine out of ten (89%) Americans diagnosed with depression and/or anxiety believe mental health medications are somewhat or very effective, yet concerns about potential side effects remain a significant barrier, preventing more than half (52%) from taking medicatio...
Myriad Genetics to Release First Quarter 2025 Financial Results on May...
Myriad Genetics to Release First Quarter 2025 Financial Results on May 6, 2025 Management will participate in two upcoming investor healthcare conferences SALT LAKE CITY, April 29, 2025 (GLOBE NEWSWIRE) -- . (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, will hold its first quarter 2025 earnings conference call at 4:30 pm EDT on Tuesday, May 6, 2025. The company’s quarterly earnings will be released the same day after the market closes. During the call, Myriad management will provide a financial overview and business update of the company’s performance ...
Myriad Genetics Highlights MRD Clinical Validity Data at American Asso...
Myriad Genetics Highlights MRD Clinical Validity Data at American Association for Cancer Research Annual Meeting Podium presentation showcases the clinical application of Precise™ MRD SALT LAKE CITY, April 25, 2025 (GLOBE NEWSWIRE) -- . (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, announced new clinical data will be shared at the American Association for Cancer Research (AACR) Annual Meeting that highlights the performance of the Precise MRD test in patients with oligometastatic clear-cell renal cell carcinoma (ccRCC). A podium presentation titled ...
Myriad Genetics Announces Study Results Show Patients with Depression ...
Myriad Genetics Announces Study Results Show Patients with Depression had Fewer Psychiatric Hospitalizations after GeneSight Testing Study published in the Journal of Clinical Psychopharmacology SALT LAKE CITY, April 21, 2025 (GLOBE NEWSWIRE) -- . (NASDAQ: MYGN), a leader in molecular diagnostics testing and precision medicine, today announced that the Journal of Clinical Psychopharmacology has published a showing those with major depressive disorder had fewer psychiatric hospitalizations after taking the ® Psychotropic Test. “Millions of Americans face major depressive disorder each ...
Myriad Genetics Announces Inducement Awards
Myriad Genetics Announces Inducement Awards SALT LAKE CITY, April 08, 2025 (GLOBE NEWSWIRE) -- . (NASDAQ: MYGN), a leader in molecular diagnostics testing and precision medicine, announced today that in connection with the hiring of Mr. Donnelly as chief commercial officer, previously announced on April 7, 2025, the Board of Directors of Myriad Genetics authorized the grant to Mr. Donnelly of restricted stock units equal to $3.75 million, comprising (i) time-based restricted stock units (RSUs) equal to $2 million and (ii) performance-based restricted stock units (PSUs) equal to $1.75 mill...
Myriad Genetics Names Brian Donnelly as New Chief Commercial Officer
Myriad Genetics Names Brian Donnelly as New Chief Commercial Officer SALT LAKE CITY, April 07, 2025 (GLOBE NEWSWIRE) -- . (NASDAQ: MYGN), a leader in molecular diagnostics testing and precision medicine, announced today the appointment of Brian Donnelly as chief commercial officer (CCO), effective May 1, 2025. A strategic, results-oriented leader with more than 20 years of experience in healthcare, diagnostics, and medical technology, Donnelly has a proven track record of building and leading high-performing teams, managing multi-billion-dollar P&Ls, and driving growth through innovative...
Myriad Genetics and Gabbi to Work Together to Increase Access to Hered...
Myriad Genetics and Gabbi to Work Together to Increase Access to Hereditary Cancer Risk Assessment Tools SALT LAKE CITY, Feb. 27, 2025 (GLOBE NEWSWIRE) -- . (NASDAQ: MYGN), a leader in molecular diagnostics testing and precision medicine, today announced a collaboration with , a telehealth solution for breast cancer risk assessment and specialist care services. The companies will work together to provide an integrated offering that combines Gabbi’s and access to with Myriad’s . “After losing my mom to breast cancer and my own breast cancer diagnosis, I am passionate about eradicat...
Myriad Genetics Reports Fourth Quarter and Full-Year 2024 Financial Re...
Myriad Genetics Reports Fourth Quarter and Full-Year 2024 Financial Results; Full-year 2024 revenue of $838 million grew 11% year-over-year, the second consecutive year of double-digit revenue growth Highlights Fourth quarter 2024 revenue of $211 million, grew 7% year-over-year driven by continued demand for Pharmacogenomics (14%) and Prenatal (12%) testing.Fourth quarter GAAP gross margin of 71.7%, increased 300 basis points year-over-year, benefiting from improving revenue per test trends and greater laboratory efficiencies.Fourth quarter and full-year 2024 GAAP net loss was $(43) millio...
Myriad Genetics Announces Senior Leadership Transition
Myriad Genetics Announces Senior Leadership Transition Appoints Sam Raha as CEO and Mark S. Verratti as COO Effective April 30, 2025 SALT LAKE CITY, Feb. 24, 2025 (GLOBE NEWSWIRE) -- . (NASDAQ: MYGN), a leader in molecular diagnostics testing and precision medicine, today announced that its Board of Directors has appointed Sam Raha, the Company’s current Chief Operating Officer (COO), as President and Chief Executive Officer (CEO) and as a member of the Board, effective April 30, 2025. Mr. Raha will replace Paul J. Diaz, who is stepping down to join private equity firm Cressey & Company...
Myriad Genetics Partners with PATHOMIQ to add Artificial Intelligence ...
Myriad Genetics Partners with PATHOMIQ to add Artificial Intelligence Technology Platform to its Oncology Portfolio SALT LAKE CITY, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, and PATHOMIQ, Inc., a developer of artificial intelligence (AI)-enabled prognostic and predictive tests for advancing access to personalized medicine and empowering treatment decisions, announced that they have entered into a strategic collaboration for Myriad to exclusively license PATHOMIQ_PRAD, PATHOMIQ’s AI technology pl...
Myriad Genetics Included in Forbes America’s Best Employers 2025 List
Myriad Genetics Included in Forbes America’s Best Employers 2025 List SALT LAKE CITY, Feb. 19, 2025 (GLOBE NEWSWIRE) -- . (NASDAQ: MYGN), a leader in genetic and genomic tumor testing and precision medicine, has been named on the Forbes list of . This prestigious recognition is presented in collaboration with Statista, the world-leading statistics portal and industry ranking provider. “Working at Myriad Genetics means being part of a dynamic team dedicated to empowering every individual by revealing the answers inside each of us. Our teammates are driven to innovate solutions that chan...
Myriad Genetics to Release Fourth Quarter and Full Year 2024 Financial...
Myriad Genetics to Release Fourth Quarter and Full Year 2024 Financial Results on February 24, 2025 Management will participate in three upcoming investor healthcare conferences SALT LAKE CITY, Feb. 18, 2025 (GLOBE NEWSWIRE) -- . (NASDAQ: MYGN), a leader in genetic and genomic tumor testing and precision medicine, will hold its fourth quarter and full year 2024 earnings conference call at 4:30 pm ET on Monday, Feb. 24, 2025. The company’s quarterly earnings will be released the same day after the market closes. During the call, Myriad management will provide a financial overview and bus...
Myriad Genetics and CancerCARE for Life Announce Agreement to Advance ...
Myriad Genetics and CancerCARE for Life Announce Agreement to Advance Access to MyRisk with RiskScore Hereditary Cancer Test SALT LAKE CITY, Feb. 06, 2025 (GLOBE NEWSWIRE) -- . (NASDAQ: MYGN), a leader in genetic and genomic tumor testing and precision medicine, and INTERLINK Care Management, Inc. announced an agreement designed to enhance education and access to hereditary cancer testing for members. The agreement enables more than one million individuals within CancerCARE’s network to assess their eligibility for the MyRisk test by taking the quiz, a guideline-based online patien...
Myriad Genetics Announces Two New Patents Granted for its Molecular Re...
Myriad Genetics Announces Two New Patents Granted for its Molecular Residual Disease (MRD) Assay SALT LAKE CITY, Feb. 05, 2025 (GLOBE NEWSWIRE) -- . (NASDAQ: MYGN), a leader in genetic and tumor genomic testing and precision medicine, announced that the United States Patent and Trademark Office has issued two new patents that further advance Myriad’s ability to bring its tumor-informed, high-definition, molecular residual disease (MRD) assay to market. US patent No. 12,215,391 relates to Myriad’s proprietary automated methods of MRD analysis. Specifically, the claims are relevant to ce...
Myriad Genetics and Lumea Collaborate to Enhance Access to the Prolari...
Myriad Genetics and Lumea Collaborate to Enhance Access to the Prolaris Biomarker and MyRisk Hereditary Cancer Tests through BxLink Integration SALT LAKE CITY, Feb. 05, 2025 (GLOBE NEWSWIRE) -- . (NASDAQ: MYGN), a leader in genetic and genomic tumor testing and precision medicine, and a leader in digital pathology solutions, have signed an agreement to integrate Myriad’s advanced molecular diagnostic tests — and – into Lumea’s digital pathology platform, BxLink™. This collaboration will streamline the ordering and delivery of molecular tests, enabling healthcare providers to electroni...
Myriad Genetics Unveils Groundbreaking Eight Weeks’ Gestation NIPT Stu...
Myriad Genetics Unveils Groundbreaking Eight Weeks’ Gestation NIPT Study Results at Society for Maternal-Fetal Medicine Conference Opening plenary session features latest fetal fraction amplification research SALT LAKE CITY, Jan. 29, 2025 (GLOBE NEWSWIRE) -- . (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced it will unveil groundbreaking research at the annual Society for Maternal-Fetal Medicine Conference (SMFM). The company’s “Fetal fraction amplification enables accurate prenatal cell-free DNA (cfDNA) screening at eight weeks gestation” study was aw...
Myriad Genetics Introduces Online Prenatal Genetic Testing Resource
Myriad Genetics Introduces Online Prenatal Genetic Testing Resource SALT LAKE CITY, Jan. 23, 2025 (GLOBE NEWSWIRE) -- . (NASDAQ: MYGN), a leader in genetic testing and precision medicine, has launched a new educational website providing comprehensive information about reproductive and prenatal genetic testing. The “” website provides the benefits and dispels the common myths of prenatal genetic testing, as well as where to get screened and what actions can be taken in the instance of a high-risk result. The site features real-life patient stories to illustrate how prenatal screening can ...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.